Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The intent of this RFP is to support non-interventional Investigator Sponsored Research projects that will advance the understanding of IB6 patterns of expression and clinical outcomes in NSCLC or explore sigvotatug vedotin’s preclinical activity.
Característiques principals
This Research Grant RFP is seeking proposals in two types of non-interventional research areas.
  • Category 1: Noninterventional, (retrospective or prospective studies) looking at integrin beta-6 (IB6) patterns of expression and clinical outcomes in NSCLC
  • Category 2: Preclinical investigator-sponsored research (not limited to NSCLC)
    • Lloc de presentació
    HMRIB and PSMAR staff who need more information should contact::
    Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: [email protected] Ext.: 1670
    Marta López: [email protected] Ext.: 1576
    Convocatòria (URL)
    https://cdn.pfizer.com/pfizercom/2025-01/GMG-2025-ONC-Global-IB6TranslationalPreclinical-RES-final.pdf?VersionId=zvcR0YkUuAxQHrRuunIGK4tRvFk8n2W9
    Application Portal:
    https://www.cybergrants.com/pls/cybergrants/ao_login.login?x_gm_id=4617&x_proposal_type_id=50610
    Requisits
  • The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a terminal degree in Pharmacy, Social Work, or other relevant discipline.
  • The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
    • Durada
    18 months

    Arxius

    Arxiu
    GMG-2025-ONC-Global-IB6TranslationalPreclinical-RES-final.pdf